



## **Ulf Wiinberg**

**Independent Director**

**Member of the Board since 2016**

**Date of birth:** 1958

**Nationality:** Danish/Swedish

**Gender:** Male

**End of term:** 2028

### **Introduction & Professional experience**

Ulf Wiinberg serves on the following listed company boards, in addition to UCB: Alfa Laval AB - Lund Sweden - as a Director, Agenus Inc, an immune oncology company - Lexington Massachusetts - as a Director and Mink Therapeutics, a clinical-stage biopharmaceutical company – as a Director.

Ulf has a long career in the Pharma industry at senior levels. Ulf was CEO at Lundbeck from June 2008 to December 2014. Ulf was also part of the Wyeth Management committee from January 2002 to June 2008. During this time Ulf was worldwide President of Wyeth Consumer Health care from 2002 to 2005, and President for Europe / Middle East / Africa until June 2008. Wyeth was acquired by Pfizer in 2009.

Lately he served as CEO of X-Vax Therapy Inc which is a privately held biotech company operating out of Jupiter Florida. The main mission of the company is to develop a vaccine and/or a therapeutic against Herpes Simplex.

Ulf has also served on the most important industry boards in different capacities.

Ulf brings to our board experience of biotechnology, pharmaceutical and healthcare industries globally.

### **Education**

Nicolai High School – 1997



**Main external appointments**

Member of the Board of Alfa Laval AB\*

Member of the Board of Agenus Inc\* and Chair of the Audit and Finance Committee

Member of the Board of Mink Therapeutics\*

\* *Listed company*

